文献速递神经儿科影像MR

儿童急性淋巴细胞白血病脑白质病的特征及其与后期神经认知表现的关系

Characterization of Leukoencephalopathy and Association With Later Neurocognitive Performance in Pediatric Acute Lymphoblastic Leukemia.
PubMed 文献 · Invest Radiol · 2021-01-01

本研究纳入377例未接受放疗的儿童急性淋巴细胞白血病患者,在治疗期间4个时间点行MR神经影像检查,并在治疗结束时及2年后行神经认知评估。结果显示巩固治疗后脑白质病患病率最高(22.8%,74/324),白质受累范围可达白质体积的10%,且早期及治疗结束时脑白质病与2年随访时神经认知表现下降、行为问题及学习困难相关。

要点

  • 巩固治疗后脑白质病患病率最高,达22.8%(74/324)。
  • 脑白质病白质受累范围可达白质体积的10%。
  • 治疗期间脑白质病与2年后神经认知表现下降及行为学习问题相关。

核心结论

  • 在未接受放疗的儿童急性淋巴细胞白血病大型队列中,治疗期间无症状脑白质病可见于近四分之一患者,白质受累范围可达白质体积的10%,并与神经认知表现下降、家长报告的行为问题及学习困难相关。

研究设计与样本

  • 研究纳入377例接受急性淋巴细胞白血病治疗且未放疗的儿童患者,在治疗期间4个时间点行MR神经影像检查:缓解诱导结束时(MR1)、巩固治疗结束时(MR2)、继续治疗第31周(MR3)及第120周(治疗结束,MR4)。
  • 在治疗结束时及2年后行神经认知评估,采用广义估计方程模型(logit链接)分析脑白质病患病率及范围与治疗时间点、诊断年龄(≤5岁或>5岁)、治疗风险组(低危或标危/高危)及性别的关系。
  • 采用一般线性模型分析治疗期间神经影像指标与2年随访时神经认知表现的关系。

关键影像表现/征象

  • 脑白质病在巩固治疗结束后患病率最高,为22.8%(74/324)。
  • 无论治疗风险组、年龄组或性别,MR2时脑白质病患病率均较MR1升高(均P<0.001;男性P<0.001,女性P=0.013)。
  • 无论治疗风险组、年龄组或性别,MR2时白质受累范围均较MR1增加(标危/高危P<0.001,低危P=0.004;各年龄组均P<0.001;男性P<0.001,女性P=0.001)。
  • 同一次检查中,脑白质病区的定量弛豫率较表现正常白质显著延长(T1 P<0.001,T2 P<0.001)。

诊断标准与关键数值

  • 脑白质病患病率最高为22.8%(74/324),见于巩固治疗后(MR2)。
  • 脑白质病白质受累范围可达白质体积的10%。
  • 脑白质病区定量弛豫率较同次检查表现正常白质延长(T1 P<0.001,T2 P<0.001)。

临床应用与阅片要点

  • 儿童急性淋巴细胞白血病治疗期间应关注脑白质病的出现及白质受累范围,巩固治疗后为患病率高峰。
  • 早期治疗阶段出现脑白质病及治疗结束时白质受累范围较大,与2年后神经认知表现下降、家长报告的行为问题及学习困难相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The most common form of pediatric cancer is acute lymphoblastic leukemia (ALL). Magnetic resonance (MR) neuroimaging studies have revealed leukoencephalopathy (LE) in pediatric ALL, but the impact of LE on long-term neurocognitive performance remains unknown. This study aims to objectively characterize the prevalence, extent, and intensity of LE, and their association with later neurocognitive performance.

MATERIALS AND METHODS: Pediatric patients (N = 377) treated for ALL without irradiation underwent MR neuroimaging at 4 time points throughout therapy (end of remission induction [MR1], end of consolidation [MR2], and week 31 [MR3] and week 120 [end therapy, MR4] of continuation treatment) and neurocognitive evaluations at the end of therapy and 2 years later. Generalized estimation equation models with logit link were developed to explore the association between LE prevalence and extent with time points throughout therapy, age at diagnosis (≤5 years or >5 years), treatment risk arm (low risk or standard/high risk), and sex. General linear models were also developed to investigate the association between neuroimaging metrics during treatment and neurocognitive performance at 2-year follow-up.

RESULTS: The prevalence of LE was greatest (22.8%, 74/324) after consolidation therapy. The prevalence of LE increased at MR2 relative to MR1 regardless of treatment risk arm (both P's < 0.001), age group (both P's < 0.001), or sex (male, P < 0.001; female, P = 0.013). The extent of white matter affected also increased at MR2 relative to MR1 regardless of treatment risk arm (standard/high risk, P < 0.001; low risk, P = 0.004), age group (both P's < 0.001), or sex (male, P < 0.001; female, P = 0.001). Quantitative relaxation rates were significantly longer in LE compared with that in normal-appearing white matter in the same examination (T1, P < 0.001; T2, P < 0.001). The LE prevalence early in therapy was associated with increased parent ratings of conduct problems (P = 0.039) and learning difficulties (P = 0.036) at 2-year follow-up compared with that at the end of therapy. A greater extent of LE early in therapy was associated with decreasing performance on a measure of processing speed (P = 0.003) from the end of therapy to 2-year follow-up. A larger extent of LE at the end of therapy was associated with decreased performance in reading (P = 0.004), spelling (P = 0.003), and mathematics (P = 0.019) at 2-year follow-up and increasing problems with attention (omissions, P = 0.045; β, P = 0.015) and memory (list A total recall, P = 0.010) at 2-year follow-up compared with that at the end of therapy.

CONCLUSIONS: In this large cohort of pediatric patients treated for ALL without irradiation, asymptomatic LE during therapy can be seen in almost a quarter of patients, involves as much as 10% of the white matter volume, and is associated with decreasing neurocognitive performance, increasing parent reports of conduct problems, and learning difficulties in survivors.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Pryweller JR, Glass JO, Sabin ND, et al. Characterization of Leukoencephalopathy and Association With Later Neurocognitive Performance in Pediatric Acute Lymphoblastic Leukemia. Invest Radiol. 2021. PMID: 32769417. doi:10.1097/RLI.0000000000000715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。